Axsome Therapeutics AXSM 深 滬
等待開盤 09-24 09:30:00 美东时间
193.45
-9.650
-4.75%
華盛通- 最 高204.695
- 今 開204.005
- 成交量 91.30万股
- 最 低 189.05
- 昨 收 203.10
- 總市值 101.33亿
- 52周最高 260.19
- 市盈率 靜 --
- 換手率 1.74%
- 52周最低 117.30
- 委 比 -55.85%
- 總股本 5238.08万
- 歷史最高 260.19
- 量 比 1.50
- 振 幅 7.70%
- 歷史最低 1.94
- 每 手 1
- 風險率 38.93%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Axsome Therapeutics Highlights Alzheimer’s Agitation Impact In Shared Goals Survey
The Shared Goals: Navigating Alzheimer’s Agitation survey finds that Alzheimer’s disease agitation is often only recognized after daily life is significantly disrupted Ninety-seven percent of care partners reported that agitation negatively impacted their loved one’s quality of life, and three in fo...
09-21 19:06
美股大行评级 | 奈飞遭看淡至57美元！现价仍有两成下行空间；Xenon制药遭多家机构降目标价，最低看至46美元
今日重点评级关注：康托·菲茨杰拉德：维持Abeona Therapeutics"超配"评级，目标价从28美元升至30美元；HC Wainwright & Co.：维持Oculis Holding"买入"评级，目标价从26美元升至39美元
09-21 16:25
Piper Sandler Reiterates Overweight on Axsome Therapeutics, Maintains $258 Price Target
Piper Sandler analyst David Amsellem reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and maintains $258 price target.
09-19 00:39
Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
Axsome Therapeutics announced new data presentations on major depressive disorder and Alzheimer’s disease agitation, along with eight additional posters, at Psych Congress 2026 in New Orleans. The data covers topics such as agitation in Alzheimer’s disease, real-world treatment patterns, care partner insights, anti-anhedonic effects of dextromethorphan-bupropion, real-world outcomes, anxiolytic effects, excessive daytime sleepiness in narcolepsy ...
09-17 11:00
Goldman rebalances its long duration stock basket
The Goldman Sachs equity team has rebalanced its Long Duration Basket amid rising interest rates. Equities usually struggle to digest sharp increases in interest rates, with long duration growth stock...
09-13 22:12
Axsome rises on Auvelity prescription data
Axsome Therapeutics (AXSM) is up ~6% in Friday trading following data showing that prescriptions for Auvelity (dextromethorphan and bupropion) reached a record high. Data from Symphony Health, part of...
09-12 01:25
美股大行评级 | Affirm、GitLab获多家大行上调目标价；Attovia获大摩、花旗首予买入评级
今日重点评级关注：杰富瑞：维持拜玛林制药"买入"评级，目标价从104美元升至105美元；RBC Capital：维持Shift4 Payments"跑赢大市"评级，目标价从63美元升至67美元
09-01 08:37
Axsome Therapeutics Dosed First Patient in SUMMIT Phase 3 Trial of AXS-05 For Smoking Cessation
Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the first patient has been dosed in the SUMMIT Phase 3 trial of AXS-05 for smoking cessation. SUMMIT (Studying NMDA and Sigma-1 in S...
08-31 19:08
Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation
Axsome Therapeutics announced the initiation of the SUMMIT Phase 3 trial for AXS-05, a novel drug targeting smoking cessation. The trial, involving 12-week treatment, will evaluate AXS-05's efficacy and safety in adult smokers, with primary endpoint being smoking abstinence. AXS-05 combines dextromethorphan and bupropion, already approved for depression and agitation. The company aims to address the significant health and economic burden of smoki...
08-31 11:00
美股大行评级 | 业绩大超预期！ CoreWeave、超微电脑、Lumentum绩后获多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Sagimet Biosciences"买入"评级，目标价从49美元升至56美元；韦德布什：维持Zura Bio"跑赢大市"评级，目标价从15美元升至22美元
08-13 11:44
